Aurobindo buys facility in US

Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, Aurobindo Pharma Limited, has announced that the company has acquired a US FDA compliant cGMP (current good manufacturing practices) facility in Dayton, New Jersey.

The facility is spread over 20 acres of freehold land and is located in Princeton Life Sciences Corridor in the state of New Jersey.

The campus comprises one lakh square feet of fully integrated R&D, formulation manufacturing and distribution facilities with potential for future expansion. This facility will serve as Aurobindo's US headquarters, a press release said.

PV Ramaprasad Reddy, chairman of Aurobindo, said that this purchase reinforced Aurobindo's commitment to serve the US market in an effective manner.